Juno Therapeutics (JUNO) Misses Q2 EPS by 23c

Juno Therapeutics (NASDAQ: JUNO) reported Q2 EPS of ($0.64), $0.23 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $14.26 million.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• Morgan Stanley Upgrades Sangfor Technologies Inc (300454:CH) to Overweight